@article{article, title  = {{MP11-13 CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (mHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL}},

 publisher = {{Ovid Technologies (Wolters Kluwer Health)}},

 url = {{https://doi.org/10.1097/ju.0000000000003226.13 }},

 year = {{2023}},

 month = {{4}},

 author = {{Jones C and Sachdeva A and Murphy L and Murray M and Brown L and McCloskey E and Brown J and Attard G and Parmar M and James N and Sydes M et al}},

 doi = {{10.1097/ju.0000000000003226.13}},

 volume = {{209}},

 journal = {{Journal of Urology}},

 issue = {{Supplement 4}},

 note = {{Accessed on 2026/06/24}}}